Wintermute Biomedical Secures $1.3M USD Funding and Commences ZOSTER EASE Phase Ib Clinical Trial for Solexan™ in Shingles Treatment

March 03, 2024•1 min read

Wintermute Biomedical has successfully raised USD 1.3 million from investors to propel its groundbreaking Shingles treatment, Solexan™, into a Phase Ib clinical trial. The primary focus of this randomized double-blind placebo-controlled trial is to assess the safety, tolerability, and proof-of-concept efficacy of Solexan™ in reducing shingles-related pain and expediting lesion healing.

Montana BioScience Alliance

Montana BioScience Alliance is the statewide organization dedicated to advancing and advocating for Montana’s bioscience industry. The Alliance connects researchers, companies, and policymakers to strengthen research, support responsible policy, and drive economic growth across the state.

Back to Blog